Medtronic to begin new blood pressure reduction trials
Courtesy Medtronic
Medtronic, with operational headquarters in Minnesota, has announced it will begin renal denervation trials.
Medtronic, a Dublin-based medical device company with offices in Littleton, announced Monday it is moving forward with a renal denervation trial after a previous study yielded positive results.
According to Medtronic, renal denervation is a minimally-invasive procedure designed to reduce hypertension during which a catheter emits a radio frequency across multiple electrodes. That energy is delivered to a renal artery to disrupt nerves.
A previous three-month study found that the first 80 patients saw “statistically significant and clinically important blood pressure reductions” in patients treated with renal denervation, according to a press release.
Blood pressure of patients in the study who underwent renal denervation saw their blood pressure decline an average of 10 mm Hg.
WBJ Web Partners
Most Recent
Most Recent
0 Comments